M&A Deal Summary |
|
|---|---|
| Date | 2016-01-27 |
| Target | Fluorinov Pharma |
| Sector | Life Science |
| Buyer(s) | Trillium Therapeutics |
| Deal Type | Add-on Acquisition |
| Deal Value | 45M CAD |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 2004 |
| Sector | Life Science |
| Employees | 33 |
Trillium Therapeutics is an immuno-oncology company developing innovative therapies for the treatment of cancer. Company lead program SIRP?Fc is an antibody-like fusion protein that blocks the activity of CD47, a molecule that allows tumor cells to escape destruction by the immune system. Trillium Therapeutics was founded in 2004 and is based in Mississauga, Ontario.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Life Science M&A | 1 of 1 |
| Type: Add-on Acquisition M&A Deals | 1 of 1 |
| State: Ontario M&A | 1 of 1 |
| Country: Canada M&A | 1 of 1 |
| Year: 2016 M&A | 1 of 1 |